Zacks highlights Zoetis (ZTS), an animal health company, as a potential momentum stock. ZTS holds a Zacks Rank of #3 (Hold) with a VGM Score of B, and its shares have risen 7.4% in the past four weeks; furthermore, ten analysts have increased their fiscal year 2025 earnings estimates in the last 60 days, raising the consensus to $6.26 per share.
Zoetis (ZTS), a significant player in the animal health sector, is presented by Zacks as a "Top Momentum Stock for the Long-Term," despite its current Zacks Rank of #3 (Hold). This assessment is supported by its 'B' grade for both its Momentum Style Score and its overall VGM Score. Further bolstering this view, ZTS shares have demonstrated recent strength, rising 7.4% over the past four weeks. Analyst sentiment is also positive, with ten analysts revising their fiscal 2025 earnings estimates upward in the last 60 days, which has pushed the Zacks Consensus Estimate for that period up by $0.18 to $6.26 per share. Additionally, Zoetis has a history of outperforming earnings expectations, boasting an average earnings surprise of 5.2%. The article suggests that these combined factors—favorable style scores, positive earnings revisions, and recent price appreciation—make ZTS a noteworthy consideration for investors, particularly those focused on momentum.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
